バイオシミラー(バイオ後続品)の世界市場見通し2016-2022

【英語タイトル】Biosimilar - Global Market Outlook (2016-2022)

Stratistics MRCが出版した調査資料(SMRC601008)・商品コード:SMRC601008
・発行会社(調査会社):Stratistics MRC
・発行日:2016年9月
・ページ数:130
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥452,350見積依頼/購入/質問フォーム
2-5 UserUSD5,250 ⇒換算¥572,250見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥817,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、バイオシミラー(バイオ後続品)の世界市場について調査・分析し、バイオシミラー(バイオ後続品)の世界市場規模、市場動向、関連企業分析などを含め、以下の構成でお届けいたします。
・エグゼクティブサマリー
・序文
・バイオシミラー(バイオ後続品)の世界市場:市場動向分析
・バイオシミラー(バイオ後続品)の世界市場:競争要因分析
・バイオシミラー(バイオ後続品)の世界市場:製品別分析/市場規模
・バイオシミラー(バイオ後続品)の世界市場:技術別分析/市場規模
・バイオシミラー(バイオ後続品)の世界市場:用途別分析/市場規模
・バイオシミラー(バイオ後続品)の世界市場:サービス別分析/市場規模
・バイオシミラー(バイオ後続品)の世界市場:地域別分析/市場規模
・バイオシミラー(バイオ後続品)の北米市場規模
・バイオシミラー(バイオ後続品)の欧州市場規模
・バイオシミラー(バイオ後続品)のアジア市場規模
・バイオシミラー(バイオ後続品)の世界市場:主な市場開拓
・関連企業分析
【レポートの概要】

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs has experienced robust market growth. Some of the factors which are triggering the market growth include growing incidences of diseases, rising demand for biosimilars drugs owing to their cost effectiveness and increasing demand to limit healthcare expenditures. However, stringent government regulations will affect biosimilars investments.

Chronic & Autoimmune disorders segment is expected to grow at a highest CAGR during the forecast period owing to increasing incidences of autoimmune disorders. By geography, Europe dominated the global biosimilars market due to growing appearance of new market participants in this region. However, Asia Pacific is anticipated to grow at a highest CAGR during the forecast period due to rising funds towards the expansion of biosimilars market.

Some of the key players in this market include are Mylan, Inc., Dr. Reddy’s Laboratories, Amgen Inc., Sandoz International GmbH , Hospira, Inc., Merck KGAA, Celltrion, Inc., Biocon Ltd. , Teva Pharmaceutical Industries Ltd. and Roche Diagnostics.

Products Covered:
• Peptides
• Erythropoietin
• Interferon
• Human Growth Hormone
• Monoclonal Antibodies
• Granulocyte Colony Stimulating Factor (G-CSF)
• Insulin
• Other Products

Technology Covered:
• Bioassay
• Mass Spectrometry
• Nuclear magnetic resonance (NMR) technology
• Recombinant DNA Technology (rDNA technology)
• Western Blotting
• Electrophoresis
• Chromatography
• Monoclonal Antibodies (MAb) Technology

Application Covered:
• Growth Hormone Deficiency
• Chronic and Autoimmune Diseases
• Blood Disorders
• Oncology Diseases
• Other Applications

Service Covered:
• Clinical Trials
• Contract Research and Manufacturing Services

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

【レポートの目次】

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 Emerging Markets

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Biosimilar Market, By Product
5.1 Introduction
5.2 Peptides
5.3 Erythropoietin
5.4 Interferon
5.5 Human Growth Hormone
5.6 Monoclonal Antibodies
5.7 Granulocyte Colony Stimulating Factor (G-CSF)
5.8 Insulin
5.9 Other Products

6 Global Biosimilar Market, By Technology
6.1 Introduction
6.2 Bioassay
6.3 Mass Spectrometry
6.4 Nuclear magnetic resonance (NMR) technology
6.5 Recombinant DNA Technology (rDNA technology)
6.6 Western Blotting
6.7 Electrophoresis
6.8 Chromatography
6.8.1 Gas Chromatography (GC)
6.8.2 Protein sequencing
6.8.3 Liquid chromatography (LC)
6.9 Monoclonal Antibodies (MAb) Technology

7 Global Biosimilar Market, By Application
7.1 Introduction
7.2 Growth Hormone Deficiency
7.3 Chronic and Autoimmune Diseases
7.3.1 Leprosy
7.3.2 Rheumatoid arthritis (RA)
7.3.3 Multiple Sclerosis
7.3.4 Diabetes
7.3.5 Acromegaly
7.3.6 Cystic Fibrosis
7.3.7 Neutropenia
7.4 Blood Disorders
7.4.1 Pulmonary embolism
7.4.2 Hemophilia
7.5 Oncology Diseases
7.5.1 Leukaemia
7.5.2 Colorectal Cancer
7.5.3 Breast Cancer
7.5.4 Prostate Cancer
7.5.5 Cervical Cancer
7.5.6 Lungs Cancer
7.6 Other Applications

8 Global Biosimilar Market, By Service
8.1 Introduction
8.2 Clinical Trials
8.2.1 Phase I
8.2.2 Phase II
8.2.3 Phase III
8.3 Contract Research and Manufacturing Services

9 Global Biosimilar Market, By Geography
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.6 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Brazil
9.4.3 Argentina
9.4.4 South Africa
9.4.5 Egypt

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Mylan, Inc.
11.2 Dr. Reddy’s Laboratories
11.3 Amgen Inc.
11.4 Sandoz International GmbH
11.5 Hospira, Inc.
11.6 Merck KGAA
11.7 Celltrion, Inc.
11.8 Biocon Ltd.
11.9 Teva Pharmaceutical Industries Ltd.
11.10 Roche Diagnostics
11.11 Biogen idec Inc.
11.12 LG Life Sciences
11.13 Synthon Pharmaceuticals, Inc.
11.14 Novartis AG

List of Tables
Table 1 Global Biosimilar Market Outlook, By Region (2013-2022) ($MN)
Table 2 Global Biosimilar Market Outlook, By Product (2013-2022) ($MN)
Table 3 Global Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
Table 4 Global Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
Table 5 Global Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
Table 6 Global Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
Table 7 Global Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
Table 8 Global Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
Table 9 Global Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
Table 10 Global Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
Table 11 Global Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
Table 12 Global Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
Table 13 Global Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
Table 14 Global Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
Table 15 Global Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
Table 16 Global Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
Table 17 Global Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
Table 18 Global Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
Table 19 Global Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
Table 20 Global Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
Table 21 Global Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
Table 22 Global Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
Table 23 Global Biosimilar Market Outlook, By Application (2013-2022) ($MN)
Table 24 Global Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
Table 25 Global Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
Table 26 Global Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
Table 27 Global Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
Table 28 Global Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
Table 29 Global Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
Table 30 Global Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
Table 31 Global Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
Table 32 Global Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
Table 33 Global Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
Table 34 Global Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
Table 35 Global Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
Table 36 Global Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
Table 37 Global Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
Table 38 Global Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 39 Global Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 40 Global Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
Table 41 Global Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
Table 42 Global Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
Table 43 Global Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
Table 44 Global Biosimilar Market Outlook, By Service (2013-2022) ($MN)
Table 45 Global Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
Table 46 Global Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
Table 47 Global Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
Table 48 Global Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
Table 49 Global Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
Table 50 North America Biosimilar Market Outlook, By Country (2013-2022) ($MN)
Table 51 North America Biosimilar Market Outlook, By Product (2013-2022) ($MN)
Table 52 North America Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
Table 53 North America Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
Table 54 North America Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
Table 55 North America Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
Table 56 North America Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
Table 57 North America Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
Table 58 North America Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
Table 59 North America Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
Table 60 North America Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
Table 61 North America Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
Table 62 North America Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
Table 63 North America Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
Table 64 North America Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
Table 65 North America Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
Table 66 North America Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
Table 67 North America Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
Table 68 North America Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
Table 69 North America Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
Table 70 North America Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
Table 71 North America Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
Table 72 North America Biosimilar Market Outlook, By Application (2013-2022) ($MN)
Table 73 North America Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
Table 74 North America Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
Table 75 North America Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
Table 76 North America Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
Table 77 North America Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
Table 78 North America Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
Table 79 North America Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
Table 80 North America Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
Table 81 North America Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
Table 82 North America Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
Table 83 North America Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
Table 84 North America Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
Table 85 North America Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
Table 86 North America Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
Table 87 North America Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 88 North America Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 89 North America Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
Table 90 North America Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
Table 91 North America Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
Table 92 North America Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
Table 93 North America Biosimilar Market Outlook, By Service (2013-2022) ($MN)
Table 94 North America Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
Table 95 North America Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
Table 96 North America Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
Table 97 North America Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
Table 98 North America Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
Table 99 Europe Biosimilar Market Outlook, By Country (2013-2022) ($MN)
Table 100 Europe Biosimilar Market Outlook, By Product (2013-2022) ($MN)
Table 101 Europe Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
Table 102 Europe Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
Table 103 Europe Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
Table 104 Europe Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
Table 105 Europe Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
Table 106 Europe Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
Table 107 Europe Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
Table 108 Europe Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
Table 109 Europe Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
Table 110 Europe Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
Table 111 Europe Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
Table 112 Europe Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
Table 113 Europe Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
Table 114 Europe Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
Table 115 Europe Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
Table 116 Europe Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
Table 117 Europe Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
Table 118 Europe Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
Table 119 Europe Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
Table 120 Europe Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
Table 121 Europe Biosimilar Market Outlook, By Application (2013-2022) ($MN)
Table 122 Europe Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
Table 123 Europe Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
Table 124 Europe Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
Table 125 Europe Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
Table 126 Europe Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
Table 127 Europe Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
Table 128 Europe Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
Table 129 Europe Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
Table 130 Europe Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
Table 131 Europe Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
Table 132 Europe Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
Table 133 Europe Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
Table 134 Europe Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
Table 135 Europe Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
Table 136 Europe Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 137 Europe Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 138 Europe Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
Table 139 Europe Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
Table 140 Europe Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
Table 141 Europe Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
Table 142 Europe Biosimilar Market Outlook, By Service (2013-2022) ($MN)
Table 143 Europe Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
Table 144 Europe Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
Table 145 Europe Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
Table 146 Europe Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
Table 147 Europe Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
Table 148 Asia Pacific Biosimilar Market Outlook, By Country (2013-2022) ($MN)
Table 149 Asia Pacific Biosimilar Market Outlook, By Product (2013-2022) ($MN)
Table 150 Asia Pacific Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
Table 151 Asia Pacific Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
Table 152 Asia Pacific Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
Table 153 Asia Pacific Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
Table 154 Asia Pacific Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
Table 155 Asia Pacific Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
Table 156 Asia Pacific Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
Table 157 Asia Pacific Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
Table 158 Asia Pacific Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
Table 159 Asia Pacific Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
Table 160 Asia Pacific Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
Table 161 Asia Pacific Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
Table 162 Asia Pacific Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
Table 163 Asia Pacific Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
Table 164 Asia Pacific Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
Table 165 Asia Pacific Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
Table 166 Asia Pacific Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
Table 167 Asia Pacific Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
Table 168 Asia Pacific Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
Table 169 Asia Pacific Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
Table 170 Asia Pacific Biosimilar Market Outlook, By Application (2013-2022) ($MN)
Table 171 Asia Pacific Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
Table 172 Asia Pacific Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
Table 173 Asia Pacific Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
Table 174 Asia Pacific Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
Table 175 Asia Pacific Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
Table 176 Asia Pacific Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
Table 177 Asia Pacific Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
Table 178 Asia Pacific Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
Table 179 Asia Pacific Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
Table 180 Asia Pacific Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
Table 181 Asia Pacific Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
Table 182 Asia Pacific Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
Table 183 Asia Pacific Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
Table 184 Asia Pacific Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
Table 185 Asia Pacific Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 186 Asia Pacific Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 187 Asia Pacific Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
Table 188 Asia Pacific Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
Table 189 Asia Pacific Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
Table 190 Asia Pacific Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
Table 191 Asia Pacific Biosimilar Market Outlook, By Service (2013-2022) ($MN)
Table 192 Asia Pacific Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
Table 193 Asia Pacific Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
Table 194 Asia Pacific Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
Table 195 Asia Pacific Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
Table 196 Asia Pacific Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
Table 197 RoW Biosimilar Market Outlook, By Country (2013-2022) ($MN)
Table 198 RoW Biosimilar Market Outlook, By Product (2013-2022) ($MN)
Table 199 RoW Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
Table 200 RoW Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
Table 201 RoW Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
Table 202 RoW Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
Table 203 RoW Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
Table 204 RoW Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
Table 205 RoW Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
Table 206 RoW Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
Table 207 RoW Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
Table 208 RoW Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
Table 209 RoW Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
Table 210 RoW Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
Table 211 RoW Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
Table 212 RoW Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
Table 213 RoW Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
Table 214 RoW Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
Table 215 RoW Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
Table 216 RoW Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
Table 217 RoW Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
Table 218 RoW Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
Table 219 RoW Biosimilar Market Outlook, By Application (2013-2022) ($MN)
Table 220 RoW Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
Table 221 RoW Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
Table 222 RoW Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
Table 223 RoW Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
Table 224 RoW Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
Table 225 RoW Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
Table 226 RoW Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
Table 227 RoW Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
Table 228 RoW Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
Table 229 RoW Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
Table 230 RoW Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
Table 231 RoW Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
Table 232 RoW Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
Table 233 RoW Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
Table 234 RoW Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 235 RoW Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 236 RoW Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
Table 237 RoW Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
Table 238 RoW Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
Table 239 RoW Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
Table 240 RoW Biosimilar Market Outlook, By Service (2013-2022) ($MN)
Table 241 RoW Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
Table 242 RoW Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
Table 243 RoW Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
Table 244 RoW Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
Table 245 RoW Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)



【レポートのキーワード】

バイオシミラー(バイオ後続品)、ペプチド、エリスロポエチン、インターフェロン、ヒト成長ホルモン

★調査レポート[バイオシミラー(バイオ後続品)の世界市場見通し2016-2022] (コード:SMRC601008)販売に関する免責事項を必ずご確認ください。
★調査レポート[バイオシミラー(バイオ後続品)の世界市場見通し2016-2022]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆